Format

Send to

Choose Destination
Molecules. 2018 Sep 27;23(10). pii: E2478. doi: 10.3390/molecules23102478.

Cannabinoid Delivery Systems for Pain and Inflammation Treatment.

Author information

1
Istituto Farmaceutico Candioli, 10092 Beinasco, Italy. natascia.bruni@candioli.it.
2
Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy. carlo.dellapepa@unito.it.
3
Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy. simona.oliaro@unito.it.
4
Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy. enrica.pessione@unito.it.
5
Department of Molecular Biotechnology and Health Sciences, University of Turin, 10125 Turin, Italy. daniela.gastaldi@unito.it.
6
Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy. franco.dosio@unito.it.

Abstract

There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and safety. The low oral bioavailability of cannabinoids has led to feasible methods of administration, such as the transdermal route, intranasal administration and transmucosal adsorption, being proposed. The highly lipophilic nature of cannabinoids means that they are seen as suitable candidates for advanced nanosized drug delivery systems, which can be applied via a range of routes. Nanotechnology-based drug delivery strategies have flourished in several therapeutic fields in recent years and numerous drugs have reached the market. This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment. Likely future directions are also considered and reported.

KEYWORDS:

cannabidiol; cannabinoids; delivery system; inflammation; pain treatment; Δ9-tetrahydrocannabinol

PMID:
30262735
DOI:
10.3390/molecules23102478
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center